论文部分内容阅读
用酶联免疫方法，试剂Cyfra21－1，测定42例健康人，23便非肿瘤性肺部疾病病人，68例肺癌病人血清中的细胞角质素片断CKS－19。健康人为1．45±0．86ng／ml，非肿瘤性肺疾病病人为1．64±1．40ng／ml。肺癌中鳞癌16例，腺癌33例，小细胞肺癌19例，Cyfra21－1阳性率各为75．0％，66．7／，31．6％。比较Cyfra21－1和CEA，NSE三种肺癌标志物的ROC曲线，Cyfra21－1的曲线最接近左上角，证明Cyfra21－1是敏感性，特异性较好的肺癌标志物。
The cytokeratin fraction CKS-19 in the serum of 42 healthy people, 23 non-neoplastic lung disease patients and 68 lung cancer patients was measured by enzyme-linked immunosorbent assay (Cyfra21-1). The healthy population was 1.45±0.86 ng/ml, and non-neoplastic lung disease was 1.64±1.40 ng/ml. There were 16 cases of squamous cell carcinoma, 33 cases of adenocarcinoma, and 19 cases of small cell lung cancer. The positive rates of Cyfra21-1 were 75.0%, 66.7/, and 31.6%, respectively. The ROC curves of Cyfra21-1, CEA and NSE lung cancer markers were compared. The curve of Cyfra21-1 was closest to the upper left corner, demonstrating that Cyfra21-1 is a sensitive and specific lung cancer marker.